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History & Examination 
A 37 year-old female presented to the emergency department having collapsed; venous glucose 
measured 50mg/dL. She reported recurrent dizziness since the birth of her fifth child 10 months 
previously and had recorded low capillary blood glucose (36-52mg/dL) when symptomatic. Her 
past history included gestational diabetes during the most recent pregnancy, treated with insulin 
aspart, insulin glargine and metformin. These therapies had been discontinued 1 month post-partum.  
Investigation 
Blood count and renal, liver, thyroid and adrenal function were all normal. HbA1c was 41mmol/mol 
(5.9%). Continuous glucose monitoring (CGM) demonstrated early-morning (asymptomatic) 
hypoglycemia and post-prandial hyperglycemia. During hypoglycemia she had high circulating 
insulin (39,181pmol/L; C-peptide 1,046pmol/L). Insulin assay was performed as previously 
described.(1) Insulin eluted from a gel filtration column in high molecular-weight fractions 
(Figure). Serum anti-insulin IgG concentration was 171mg/L (0-5).  
We diagnosed insulin autoimmune syndrome (IAS), a term commonly used in patients without 
previous exposure to exogenous insulin. Here, we cannot exclude that the insulin antibodies 
generated were in response to exogenous insulin, but severe hypoglycemia did not develop until 
many months after cessation of insulin therapy. Moreover, antibodies developing after exposure to 
exogenous insulin rarely bind insulin with sufficient capacity or affinity to perturb glycemia.(2)  
The patient was fitted with CGM with hypoglycemia alarm and prescribed a diet of frequent low 
glycemic-index carbohydrate meals. As significant hypoglycemia continued, prednisone was 
commenced (1mg/kg/day) and titrated according to CBG readings to 10mg/day over three months. 
To reduce anti-insulin antibodies, we gave the anti-CD20 monoclonal antibody rituximab.  
Repeat CGM after six weeks revealed intermittent hypoglycemia and sustained daytime 
hyperglycemia. Over months, there were reductions in total insulin, anti-insulin antibody 
concentration and antibody-bound insulin (Figure). These were associated with reduced 
 
 
3
hypoglycemia and improved hypoglycemic awareness. By 6 months, hypoglycemia was rare and 
post-prandial hyperglycemia had improved (CGM peak glucose 162.0mg/dL). There were no 
adverse events and prednisone was discontinued after 10 months, after which no further 
hypoglycemia was recorded.  
Recurrent hypoglycemia is associated with endothelial dysfunction, inflammation and increased 
cardiovascular risk.(3) Thus, we explored the cardiovascular phenotype associated with IAS, before 
and after treatment. Carotid-femoral pulse wave velocity (PWV) was 7.6m/s at presentation and 
5.2m/s at 6 months (5.2-8.0m/s); there was no change in blood pressure over this period. This 
suggests elevated arterial stiffness at presentation, associated with cardiovascular risk. Other 
surrogate markers of endothelial dysfunction were all higher at disease presentation than at 6 
months (Figure). Circulating miR-126 rose following treatment (Figure). This microRNA is 
endothelial-enriched and is thought to maintain endothelial homeostasis and promote 
vasculogenesis.(4) There was minimal change in control miR-122-5p. 
Conclusions 
Treatment of IAS is poorly defined. Historically, glucocorticoids and plasmapharesis were used for 
refractory cases. We show that B-cell depletion with rituximab induces a sustained reduction in 
anti-insulin antibodies, circulating insulin and the frequency of hypoglycemia. Rituximab has been 
used successfully in two other cases of IAS.(5,6) However in one, concomitant use of 
plasmapheresis, methotrexate and intravenous immunoglobulin make it difficult to ascribe the 
beneficial therapeutic effect to rituximab.  
Our report is novel in providing data to suggest an adverse vascular phenotype in IAS that is 
reversible when dysglycemia resolves. We speculate that recurrent dysglycemia may contribute to 
vascular dysfunction in IAS, but further study is required to determine the underlying mechanism.  
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Figure: (A) Reportable insulin concentration, total insulin estimation & free insulin estimation against time. Day 
0 is the day of first presentation; prednisone was commenced on day 44; rituximab was administered on days 44 and 58. 
Insulin concentrations shown here were measured using the DiaSorin LIAISON® assay; an alternative assay (Abbot 
Architect®) gave consistent results. Follow-up insulin determination was undertaken on neat plasma (‘measured 
insulin’) and after 1:49 dilution in 0.9% saline to promote insulin-antibody dissociation and reduce negative assay 
interference by antibodies (‘total insulin’) as well as in supernatant following polyethylene glycol precipitation (‘free’ 
insulin). ○ represents measured insulin concentration >3000pmol/L in neat plasma. (B) Serum anti-insulin IgG 
concentration (in-house ImmunoCAP® assay; reference range 0-5). (C) Changes in plasma macroinsulin in 
response to immunosuppressive therapy. At presentation, only 4% of total immunoreactive insulin was recovered 
from plasma supernatant following polyethylene glycol precipitation, consistent with the presence of high molecular-
weight insulin immunoreactivity. Predominantly high molecular-weight insulin consistent with macroinsulin was 
demonstrable using gel filtration chromatography at presentation. The elution volumes of immunoglobulin and 
monomeric insulin are shown by the black and white arrows respectively; the majority of insulin co-eluted with 
immunoglobulins. Follow-up investigations on day 271 confirmed a decrease in macroinsulin. (D) Changes in 
circulating markers of endothelial / vascular function at presentation (‘pre’) and at 6 months (‘post’). ADMA, 
asymmetric dimethylarginine; ET-1, endothelin-1.  
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